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Abstract
Objectives The Contrast Media Safety Committee (CMSC) of the European Society of Urogenital Radiology (ESUR) has
updated its 2011 guidelines on the prevention of post-contrast acute kidney injury (PC-AKI). The results of the literature review
and the recommendations based on it, which were used to prepare the new guidelines, are presented in two papers.
Areas covered in part 2 Topics reviewed include stratification of PC-AKI risk, the need to withdraw nephrotoxic medication, PC-
AKI prophylaxis with hydration or drugs, the use of metformin in diabetic patients receiving contrast medium and the need to
alter dialysis schedules in patients receiving contrast medium.
Key points
• In CKD, hydration reduces the PC-AKI risk
• Intravenous normal saline and intravenous sodium bicarbonate provide equally effective prophylaxis
• No drugs have been consistently shown to reduce the risk of PC-AKI
• Stop metformin from the time of contrast medium administration if eGFR < 30 ml/min/1.73 m2
• Dialysis schedules need not change when intravascular contrast medium is given
Keywords Contrast media . Acute kidney injury .Metformin . Haemodialysis . Practice guidelines
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Introduction
The Contrast Media Safety Committee (CMSC) of the
European Society of Urogenital Radiology (ESUR) pro-
duced their most recent guidelines on what was then
termed contrast-induced nephropathy (CIN) in 2011 [1].
Guidelines on the use of contrast media (CM) in patients
on dialysis and on the use of CM in diabetic patients
using metformin were published in 2002 and 2014 [2,
3]. This review provides recommendations for updating
the CMSC guidelines which were obtained using a struc-
tured literature review based on clinical questions and
Patient–Intervention–Comparator–Outcome (PICO) for-
matting. Since the literature related to the topics consid-
ered is so large, the results of the review have been split
into two papers. The review only considers post-contrast
kidney injury (PC-AKI) after iodine-based CM because
acute kidney injury is not associated with gadolinium-
based contrast agents in doses approved for clinical mag-
netic resonance imaging.
In this second paper on PC-AKI, the following topics re-
lated to patient management are considered:
1. The role of questionnaires and risk scores to identify at-
risk patients with reduced renal function
2. The need to stop nephrotoxic medication before giving
CM
3. The optimal hydration protocols for protecting against
PC-AKI
4. The possible role of prophylactic drug treatment in
preventing PC-AKI
5. The need to adapt metformin administration when giving
CM
6. The need to alter schedules for dialysis in the period be-
fore and after CM administration
Recommendations are made for items 1–6. The recommen-
dations have been incorporated into version 10 of the ESUR
CMSC guidelines, at the end of this paper (Table 4).
Materials and methods
The recommendations were prepared using the Appraisal
of Guidelines for Research and Evaluation (AGREE) II
document [4]. A guideline Writing Group (WG) prepared
ten clinical questions in PICO format [5]. Systematic
search strings were developed with a professional librari-
an for four different biomedical literature databases
(PubMed, Web of Science, Embase and the Cochrane
Library). The titles and abstracts were screened for rele-
vance and selected on predefined inclusion and exclusion
criteria. Emphasis was put on comparative studies with
strong scientific evidence, such as meta-analyses and sys-
tematic reviews, and prospective randomised controlled
trials (RCTs). The six systematic searches in this manu-
script yielded 3402 references of which 445 were selected
on the basis of title and abstract. After review of the full
text of these 445 publications, 145 were selected for in-
clusion in this paper. The quality of the evidence from the
selected articles was evaluated according to the Oxford
Centre for Evidence Based Medicine levels of evidence:
grade A, established scientific evidence; grade B, scien-
tific presumption; grade C, low level of evidence [6].
When there was no scientific evidence, recommendations
were based on WG consensus and were graded as expert
opinion (grade D).
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The full description of the materials and methods appears
in part 1.
The term intra-arterial injection with first pass renal
exposure indicates that contrast medium reaches the kid-
neys in a relatively undiluted form, e.g. injection into the
left heart, thoracic and suprarenal abdominal aorta or the
renal arteries. The term intra-arterial injection with second
pass renal exposure indicates that contrast medium
reaches the renal arteries after dilution either in the pul-
monary or peripheral circulation, e.g. injection into the
right heart, pulmonary artery, carotid, subclavian, coro-
nary, mesenteric or infrarenal arteries.
Results
Question 5: Should questionnaires or scoring systems
be used for risk stratification by clinicians when they
request a contrast-enhanced imaging study?
Patient questionnaires
Questionnaires, such as that proposed by Choyke [7], use
information about a history of renal disease or renal sur-
gery, heart failure, diabetes, proteinuria, hypertension and
gout to stratify patients for their PC-AKI risk so that sCr
measurements need only be done selectively. This may
work well and can save resources [8]. Observational stud-
ies have shown that these questionnaires can identify pa-
tients with eGFR < 45 ml/min/1.73 m2 with adequate
sensitivity, especially if they are aged less than 70
[9–11]. Since eGFR measurement can detect more pa-
tients with renal dysfunction than questionnaires [12],
wi th eas i e r pa t ien t log is t i cs and s imi la r cos t -
effectiveness [13, 14], many hospitals have adopted a pol-
icy of sCr measurements in all patients scheduled for in-
travenous (IV) CM and no longer use questionnaires for
risk stratification or selection for eGFR measurement
(Table 1).
Risk prediction models
No risk models have been produced yet for IV or IA CM
administration with second pass renal exposure. For pa-
tients having coronary angiography (CA) or percutaneous
coronary intervention (PCI), many different risk scores
have been proposed to stratify the patient’s PC-AKI risk,
and most include pre-procedural and procedural data. A
model with only pre-procedural data [15] would be more
practical for selecting suitable preventive measures. Risk
scores should be verified in relation to improvements in
clinical outcome. In clinical practice, a prediction rule
would require a high discriminatory value, i.e. a C-
statistic greater than 0.80 [16].
The best-known risk model is the eight-variable Mehran
score [17], which has been studied in more than 15,000 pa-
tients and has been externally validated inmultiple studies, but
with variable C-statistic values of 0.57–0.85 [16, 18–20]. The
Mehran score correlates relatively well with clinical outcomes
[21]. Newer risk scores with good discriminatory value, avail-
able in user-friendly calculators or smartphone applications,
still need external validation [22]. A recent systematic review
of 16 risk models concluded that they had only modest pre-
dictive value [23] and a review and meta-analysis of 74 risk
models noted their heterogeneity and concluded that further
research was needed to evaluate the effect of such models on
clinical care [24] (Table 1).
Question 6: Should nephrotoxic medication be
withheld to reduce the risk of PC-AKI?
Optimal nephrologic care involves minimizing the use of
nephrotoxic drugs where clinically possible [25]. Many fre-
quently prescribed medications, such as nonselective
NSAIDs, selective Cox-2 inhibitors, several classes of
Table 1 PC-AKI: Risk stratification; use of nephrotoxic medication
Risk stratification
In hospitals which use sCr measurements for all patients before
intravascular CM administration there is no benefit in using
questionnaires for PC-AKI risk stratification.
In hospitals which use sCr measurements selectively, Choyke
questionnaires may be used to identify patients with eGFR < 45
ml/min/1.73 m2 before intra-arterial CM administration with first pass
renal exposure.
Level of evidence D
Risk prediction scores are only available for coronary angiography and/or
percutaneous coronary intervention, and have only modest abilities, so
cannot be recommended to stratify the risk of PC-AKI.
Level of evidence A
Nephrotoxic medication
In CKD patients receiving CM, optimal nephrologic care involves
minimising the use of nephrotoxic drugs.
Level of evidence D
ACE inhibitors and angiotensin receptor blockers do not have to be
stopped before CM administration.
Level of evidence B
There is insufficient evidence to recommend withholding nephrotoxic
drugs such as NSAIDs, antimicrobial agents or chemotherapeutic
agents before CM administration.
Level of evidence C
2858 Eur Radiol (2018) 28:2856–2869
antimicrobial agents and chemotherapeutic agents have neph-
rotoxic potential and can induce AKI [26].
There is little good quality data about the relationship
between these drugs and PC-AKI [27]. A retrospective
cohort study showed that concurrent use of four or more
nephrotoxic agents was significantly predictive for PC-
AKI in patients given IV CM [28]. A meta-analysis of
PC-AKI incidence following CM-enhanced CT found that
concurrent administration of NSAIDs was an independent
risk factor for PC-AKI [29].
The effect of withholding angiotensin converting en-
zyme inhibitors (ACEI) and angiotensin-2 receptor
blockers (ARB) in chronic users has been extensively
evaluated. Multiple RCTs [30, 31] and observational stud-
ies gave conflicting results and are limited by small sam-
ple sizes and significant heterogeneity [32–34]. However,
meta-analyses of RCTs found no lower risk [34].
Withholding ACEI/ARB may be associated with a slight-
ly lower risk of PC-AKI but the evidence is not sufficient-
ly strong to recommend this (Table 1).
Question 7: What are the most cost-
and time-effective protocols for oral and intravenous
hydration to reduce the risk of PC-AKI?
Hydration as a preventive strategy for PC-AKI
Evidence for prevention of PC-AKI with IV saline hydration
(volume expansion) comes from RCTs in patients who re-
ceived intra-arterial (IA) CM during percutaneous interven-
tion [35–37], and in patients who received bicarbonate hydra-
tion before IV enhanced emergency CTPA [38]. One RCT
evaluated the evidence for IA CM administration during CA
[39]. These studies found that, for both IA and IV CM admin-
istration, the incidence of PC-AKI was significantly lower in
patients who received IV hydration compared to placebo, and
that hydration prevented emergency dialysis [36]. Significant
differences for mortality or other adverse events were not
found. There were few patients with severe renal impairment
(eGFR < 30 ml/min/1.73 m2) in almost all studies. The recent
AMACING trial showed that for patients with eGFR > 30 ml/
min/1.73 m2 receiving IV CM there was no difference be-
tween no hydration and hydration in preventing PC-AKI [40].
Oral hydration versus intravenous saline hydration
Oral intake of clear fluids by patients as an alternative to
IV saline to prevent PC-AKI is difficult to monitor or
control. Nine studies evaluated oral hydration, but were
limited by small patient numbers and by the absence of
patients with severe renal impairment [39, 41–48]. Three
meta-analyses concluded that there is no evidence that
oral hydration is associated with more risk of PC-AKI
compared to IV hydration, but the studies were limited
by heterogeneity and lack of hard clinical outcomes
[49–51]. The CMSC does not recommend the use of oral
hydration as the sole preventive strategy for PC-AKI, but
unrestricted intake of clear oral fluids in addition to IV
volume expansion is supported (Table 2).
Table 2 PC-AKI prophylaxis: Hydration, drugs, renal replacement therapy
Hydration
Preventive hydration should be used to reduce the incidence of PC-AKI
in at-risk patients.
Level of evidence B
Intravenous saline and bicarbonate protocols have similar efficacy for
hydration.
Level of evidence A
For intravenous and intra-arterial CM administration with second pass
renal exposure hydrate the patient with either (a) 3 ml/kg/h bicarbonate
1.4% (or 154 mmol/l solution) for 1 h before CM or (b) 1 ml/kg/h
saline 0.9% for 3–4 h before and 4–6 h after CM.
Level of evidence D
For intra-arterial CM administration with first pass renal exposure hydrate
the patient with either (a) 3 ml/kg/h bicarbonate 1.4% (or 154 mmol/l
solution) for 1 h before CM followed by 1 ml/kg/h bicarbonate 1.4%
(or 154 mmol/l) for 4–6 h after CM
or (b) 1 ml/kg/h saline 0.9% for 3–4 h before and 4–6 h after CM.
Level of evidence D
Oral hydration as the sole means of prevention is not recommended.
Level of evidence D
In patients with severe heart failure (NYHA grade 3–4) or patients with
end-stage renal failure (CKD grade V) preventive IV hydration should
be individualized by the clinician responsible for patient care.
Level of evidence D
Drugs
N-Acetylcysteine has not been conclusively shown to reduce the risk of
PC-AKI in patients with eGFR < 45 ml/min/1.73 m2 receiving
intravenous or intra-arterial CM, and its use is NOT recommended.
Level of evidence A
Giving short-term, high-dose statins to patients not already taking statins
has not been shown to reduce the risk of PC-AKI in patients with eGFR
< 45ml/min/1.73 m2 receiving intravenous or intra-arterial CM, and its
use is NOT recommended.
Level of evidence B
ACE inhibitors or angiotensin receptor blockers have not been shown
conclusively to reduce the risk of PC-AKI in patients receiving
intravenous or intra-arterial CM, and their use is NOT recommended.
Level of evidence B
Vitamin C has not been shown conclusively to reduce the risk of PC-AKI
in patients receiving intravenous or intra-arterial CM, and its use is
NOT recommended.
Level of evidence B
Renal replacement therapy
Renal replacement therapy has not been shown conclusively to reduce the
risk of PC-AKI in patients receiving intravenous or intra-arterial CM,
and its use is NOT recommended.
Level of evidence B
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Intravenous hydration: saline versus bicarbonate
Normal saline (NaCl 0.9%) and sodium bicarbonate solution
(1.4% or 154 mmol NaHCO3 in D5W) are the two most com-
monly studied crystalloid solutions. The rationale for using
bicarbonate is that alkalinisation can reduce the formation of
free reactive oxygen species [52]. Initial studies favoured bi-
carbonate [53–56], but this was not replicated in later studies
[57–62], so IV hydration with bicarbonate can be considered
equivalent to normal saline.
There is no consensus on the optimal hydration re-
gime. Most studies have compared bicarbonate given
pre- and post-CM for less than 6 h [53] to longer dura-
tion saline pre- and post-CM protocols (12–24 h). In all
studies, there are few patients with eGFR < 30 ml/min/
1.73 m2, and evidence about whether short duration bi-
carbonate is better than long duration saline is conflicting
[63–71]. There is limited evidence on whether pre-
hydration only is inferior to pre- and post-hydration,
and only one very short duration bicarbonate protocol
has been evaluated [38, 72, 73].
Most studies have been performed in cardiac patients ad-
mitted for CA or PCI. Three studies evaluated hydration pro-
tocols in patients having contrast-enhanced CT, and did not
favour bicarbonate over saline [38, 72, 74]. No studies were
identified assessing the beneficial effect of other crystalloids.
However, balanced crystalloid solutions, such as Ringer’s lac-
tate, may be preferable in critical care populations, because
they avoid the harmful effects of hyperchloraemic acidosis.
The CMSC considers that for IV and IA CM injection
with second pass renal exposure either a short bicarbonate
hydration regime before CM or a conventional protocol with
saline given before and after CM may be used. For IA CM
injection with first pass renal exposure conventional proto-
cols with either bicarbonate or saline given before and after
CM should be used (Table 2).
Forced diuresis versus conventional hydration
Newer approaches for patients with impaired left ventricular
function combine controlled saline hydration with a forced
high urinary flow rate to maintain euvolemia and avoid
overhydration and several RCTs showed better results than
conventional hydration protocols [75–77]. Other catheter-
based strategies used left ventricular end-diastolic pressure
or central venous pressure to guide hydration [78, 79]. In
these RCTs the incidence of PC-AKI was lower than with
standard IV hydration. Since the forced diuresis studies have
heterogeneous populations, interventions and control hydra-
tion protocols, their findings cannot be pooled. The CMSC
considers that there is not sufficient evidence to recommend
forced diuresis.
In which patients should the hydration protocol be
individualized?
There is no data to suggest that patients with severe renal
impairment (CKD grade V) or severe heart failure (NYHA
grade 3–4) should receive different hydration protocols.
However, IV hydration with large volumes may exacerbate
acute heart failure and induce pulmonary oedema [40]. The
opinion of the CMSC is that hydration protocols in these
patients should be individualized for type, volume and
duration.
Question 8: Which other strategies (pharmaceutical,
vitamin, renal replacement therapy) have been
proved effective in preventing PC-AKI?
N-Acetylcysteine (NAc)
Most recent RCTs or meta-analyses do not show a protective
effect of NAc against PC-AKI following coronary or periph-
eral angiography [66, 80–84]. NAc also failed to affect clinical
outcome in coronary or peripheral angiography [85] or to have
a protective effect in CT [86, 87] or in patients with diabetes
mellitus undergoing coronary or peripheral angiography [88,
89]. Comparative studies with NAc combined with saline or
sodium bicarbonate protocols did not show any additional
effect of protective effect of NAc [61, 90–93]. However, more
recent meta-analyses showed a benefit of NAc, with or with-
out high-dose statins, when added to hydration for preventing
PC-AKI [94–96].
Statins
Several meta-analyses showed lower overall PC-AKI rates
with the use of high-dose, short-term statin treatment
compared to controls [95–105]. Lower PC-AKI rates were
also found in subgroups, such as older patients, patients
with acute coronary syndromes and for high-dose statin
regimes. Some of these meta-analyses showed a reduced
need for RRT after statins, but no reduction in all-cause
mortality [97, 102]. However, the US Agency for
Healthcare Research and Quality (AHRQ) meta-analysis
showed that the risk of PC-AKI was only significantly
reduced when statins were added to hydration and NAc.
A reduction in PC-AKI risk could not be shown when
statins plus hydration were compared to hydration alone
in patients not taking statins. The standard of evidence
grade was low in both analyses [94].
Despite the many positive results, it is difficult to make a
general recommendation for statins [106] because the patients
studied were invariably cardiac, and a variety of statin and
hydration protocols were used. Patients with CKD grade
3B–5 (eGFR < 45 ml/min/1.73 m2) are under-represented in
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the studies and results in these patients remain inconclusive
[102, 103, 107, 108]. Most patients undergoing CA/PCI are
already taking long-term statins, and results in these patients
are unclear.
While the CMSC recognises the potential preventive ef-
fects of short-term statins, it does not advise the use of short-
term, high-dose statins as a single strategy for preventing PC-
AKI (Table 2).
RAAS blockade: ACE inhibitors and angiotensin-II receptor
blockers
Administration of renin–angiotensin–aldosterone system
(RAAS) blockade as a preventive measure for patients not tak-
ing these drugs did not show a significant effect on the inci-
dence of PC-AKI in recent meta-analyses [32, 34] (Table 2).
Vitamin C
The majority of RCTs or meta-analyses do not demon-
strate a protective effect of vitamin C against PC-AKI in
patients with CKD predominantly undergoing coronary
angiography [109–111] or any benefit of the use of vita-
min C, NAc or a combination of both over the standard
hydration regimen in preventing PC-AKI [112, 113]
(Table 2). Combining vitamin C with pentoxifylline also
failed to show an advantage [114]. Only two publications
[115, 116] have shown a protective effect of vitamin C in
patients with CKD undergoing CA.
Renal replacement therapy (RRT)
There is no convincing evidence in favour of preventive
haemodialysis or RRT alone [117–119] or combined with hy-
dration [120] in patients with CKD, predominantly undergo-
ing CA (Table 2). There is no evidence of an increased risk of
permanent anuria in patients on peritoneal dialysis undergoing
CA [121]. There is a single study showing better late-stage
(day 5–30) renal protection against PC-AKI with simulta-
neous haemodialysis [122].
Miscellaneous
The data on the protective effects of several agents, such
as trimatizidine [123, 124], theophylline [95, 125–127],
alprostadil [128, 129], nebivolol [130], fenoldopam [131]
and iloprost [132], is not conclusive and does not sup-
port recommending their use to reduce the risk of PC-
AKI.
Question 9: Should administration of metformin be
adapted to reduce the risk of metformin-associated
lactic acidosis in patients with type 2 diabetes mellitus
scheduled to receive intravascular contrast media?
Metformin is the standard drug for monotherapy of type 2
diabetes mellitus [133]. The effect of CM on the risk of
metformin-associated lactic acidosis is indirect, since an epi-
sode of AKI following intravascular CM administration may
lead to metformin accumulation. The use of metformin in
patients with eGFR 30–59 ml/min/1.73 m2 is considered safe
if doses are reduced appropriately [134, 135]. Limiting the
metformin dose to a maximum of 2000 mg/day for eGFR
45–60 ml/min/1.73 m2 and to a maximum of 1000 mg/day
for eGFR 30–44 ml/min/1.73 m2 has been recommended. In
patients with eGFR 30–59 ml/min/1.73 m2 metformin drug
levels remain within therapeutic ranges. For patients with
eGFR < 30 ml/min/1.73 m2 metformin administration is not
approved.
Multiple studies and meta-analyses have shown that the
risk of lactic acidosis is very low and linked more to the
underlying disease and possible co-morbidities rather than
the use of metformin [134, 136, 137]. Because of the lack of
published evidence on metformin and CM, early guidelines
about the need to stop metformin before intravascular CM
were based on consensus, and were strict [138, 139]. As the
low risk of lactic acidosis became apparent, guidelines have
become less restrictive [3].
Since no new published evidence is available, the CMSC
has updated its recommendations based on recent
Table 3 Metformin administration, dialysis schedules
Metformin administration in patients at risk of PC-AKI
Note that these recommendations may deviate from current EMA/FDA
recommendations.
Patients with eGFR > 30 ml/min/1.73 m2 and no evidence of AKI
receiving either intravenous CM or intra-arterial CM with second pass
renal exposure: continue taking metformin normally.
Patients (a) with eGFR < 30 ml/min/1.73 m2 receiving either intravenous
CM or intra-arterial CM with second pass renal exposure or (b)
receiving intra-arterial CM with first pass renal exposure or (c) with
AKI: stop taking metformin from the time of CM administration:
measure eGFR within 48 hours and restart metformin if renal function
has not changed significantly.
Level of evidence D
Dialysis schedules in relation to CM administration
It is not necessary to adapt the timing of intravascular CM administration
in relation to the dialysis schedule in patients undergoing chronic
dialysis or haemofiltration, but it may be done to minimise volume
overload.
Level of evidence D
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Table 4 ESUR CMSC guideline
(version 10) for post-contrast
acute kidney injury (PC-AKI)
Definitions
Post-contrast acute kidney injury (PC-AKI) is defined as an increase in serum creatinine ≥ 0.3 mg/dl (or ≥ 26.5
μmol/l), or ≥ 1.5 times baseline, within 48–72 h of intravascular administration of a contrast medium.
Intra-arterial injection with first pass renal exposure indicates that contrast medium reaches the renal arteries
in a relatively undiluted form, e.g. injection into the left heart, thoracic and suprarenal abdominal aorta or the
renal arteries.
Intra-arterial injection with second pass renal exposure indicates that contrast medium reaches the renal
arteries after dilution either in the pulmonary or peripheral circulation e.g. injection into the right heart,
pulmonary artery, carotid, subclavian, coronary, mesenteric or infra-renal arteries.
Measurement of renal function
• Estimated glomerular filtration rate (eGFR), calculated from the serum creatinine, is recommended to
estimate renal function before administration of contrast medium.
• In adults ≥ 18 years, the CKD-EPI formula to estimate GFR is recommended.
eGFR (ml/min/1.73 m2) =
Female sCr ≤ 62 μmol/l: 144 × (sCr/62)−0.329 × 0.993Age
Female sCr > 62 μmol/l: 144 × (sCr/62)−1.209 × 0.993Age
Male sCr ≤ 80 μmol/l: 141 × (sCr/80)−0.411 × 0.993Age
Male sCr > 80 μmol/l: 141 × (sCr/80)−1.209 × 0.993Age
(sCr in μmol/l; age in years)
All equations × 1.159 if African American race
• In children, the revised Schwartz formula to estimate GFR is recommended,
eGFR (ml/min/1.73 m2) = 36.5 × Length/sCr (sCr in μmol/l; length in cm)
Note: Neither serum nor plasma creatinine is an ideal indicator of renal function and may miss decreased renal
function.
Renal adverse reactions to iodine-based contrast media
RISK FACTORS FOR PC-AKI
Patient-related • eGFR less than 45 ml/min/1.73 m2 before intra-arterial contrast
medium administration with first pass renal exposure or in ICU
patients
• eGFR less than 30 ml/min/1.73 m2 before intravenous contrast
medium or intra-arterial contrast medium administration with second
pass renal exposure
• Known or suspected acute renal failure
Procedure-related • Intra-arterial contrast medium administration with first pass renal
exposure
• Large doses of contrast medium given intra-arterially with first pass
renal exposure
• High osmolality contrast media
• Multiple contrast medium injections within 48-72h
Time of referral
ELECTIVE EXAMINATION
MEASUREMENT OF RENAL FUNCTION
• Measure eGFR before administering intravascular iodine-based contrast medium
either (a) In all patients
or (b) In patients who have a history of
- Renal disease (eGFR < 60 ml/min/1.73 m2)
- Kidney surgery
- Proteinuria
- Hypertension
- Hyperuricemia
- Diabetes mellitus
• Timing of eGFR measurement
- Within 7 days before contrast medium administration in patients with an acute disease, an acute
deterioration of a chronic disease or who are hospital inpatients
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Table 4 (continued)
- Within 3 months before contrast medium administration in all other patients
EMERGENCY EXAMINATION
Identify at-risk patients (see above), if possible:
• Determine eGFR if the procedure can be deferred until the result is available without harm to the patient.
• If eGFR cannot be obtained, follow the protocols for patients with eGFR less than 45 ml/min/1.73 m2 for intra-
arterial administration with first pass renal exposure and eGFR less than 30 ml/min/1.73 m2 for intravenous and
intra-arterial administration with second pass renal exposure as closely as clinical circumstances permit.
Before the examination
ELECTIVE EXAMINATION
At-risk patients (see above) • Consider an alternative imaging method not using iodine-based
contrast media
• Intravenous saline and bicarbonate have similar efficacy for preventive
hydration
• For intravenous contrast media administration and intra-arterial
contrast media administration with second pass renal exposure hydrate
the patient either with intravenous sodium bicarbonate 1.4% (or 154
mmol/l in dextrose 5%water): 3 ml/kg/h for 1 h before contrast medium
or with intravenous saline 0.9%, 1 ml/kg/h for 3–4 h before and 4–6 h
after contrast medium
• For intra-arterial contrast media administration with first renal
exposure hydrate the patient eitherwith intravenous sodium bicarbonate
1.4% (or 154mmol/l in dextrose 5%water): 3 ml/kg/h for 1 h before and
1 ml/kg/h for 4–6 h after contrast medium or with intravenous saline
0.9%, 1 ml/kg/h for 3–4 h before and 4–6 h after contrast medium
• The clinician responsible for patient care should individualize
preventive hydration in patients with severe congestive heart failure
(NYHA grade 3–4) or patients with end-stage renal failure (eGFR < 15
ml/min/1.73 m2)
• Oral hydration is not recommended as the sole method of preventive
hydration
EMERGENCY EXAMINATION
At-risk patients (see above) • Consider an alternative imaging method not using iodine-based
contrast media
• Use preventive hydration before contrast medium administration (see
‘Elective Examination’ for protocols)
Time of examination
All patients • Use low or iso-osmolar contrast media
• Use the lowest dose of contrast medium consistent with a diagnostic
result
• For intra-arterial contrast medium administration with first pass renal
exposure keep either the ratio CM dose (in gram I)/absolute eGFR (in
ml/min) < 1.1 or the ratio CM volume (in ml)/eGFR (in ml/min/1.73
m2) < 3.0 (assuming a contrast medium concentration of 350 mg iodine/
ml)
After the examination
At-risk patients • Continue preventive hydration if appropriate (see protocols above)
• Determine eGFR 48 h after administration of contrast medium
• If at 48 h there is a diagnosis of PC-AKI, monitor the patient clinically
for at least 30 days and determine eGFR at regular intervals
Note: No pharmacological prophylaxis (with statins, renal vasodilators, receptor antagonists of endogenous
vasoactive mediators or cytoprotective drugs) has been shown to offer consistent protection against PC-AKI.
Patients with diabetes mellitus taking metformin
• Patients with eGFR > 30 ml/min/1.73 m2 and no evidence of AKI receiving either intravenous or intra-arterial
iodine-based contrast medium with second pass renal exposure: Continue taking metformin normally.
• Patients (a) with eGFR < 30 ml/min/1.73 m2 receiving either intravenous or intra-arterial contrast medium with
second pass renal exposure or
(b) receiving intra-arterial contrast medium with first pass renal exposure or
(c) with AKI:
Stop taking metformin from the time of contrast medium administration. Measure eGFR within 48 h and restart
metformin if renal function has not changed significantly.
Dialysis and contrast medium administration
• All iodine-based contrast media can be removed by haemodialysis or peritoneal dialysis.
• There is no evidence that haemodialysis protects patients with normal or impaired renal function from PC-AKI.
• In all patients, avoid osmotic and fluid overload.
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recommendations from the FDA [140], and on guidelines
from the ACR and RSTN [14, 141] (Table 3).
Question 10: Should the timing of CM administration
be adapted to the schedule of haemodialysis
or haemofiltration sessions in patients on renal
replacement therapy?
Iodine-based CM can be safely removed by haemodialysis
(HD) or haemofiltration (HF). Many factors influence the ef-
fectiveness of HD, such as flow rate of blood and dialysate,
dialysis membrane permeability, HD duration, and CM char-
acteristics such as molecular size, protein binding, hydrophi-
licity and electrical charge [142].
Although HF concomitant with radiological procedures
has been shown to be feasible and well tolerated [143, 144],
the fractional removal of iodine-based CM contrast agents is
modest and several HF or HD sessions are needed to remove
95% of the administered CM [143]. Also, there is no evidence
for the necessity of emergency HD after administration of
iodine-based CM in patients on chronic HD [145]. However,
to avoid volume overload, CM administration may be
synchronised with scheduled HF or HD (Table 3).
Conclusion
Assessment of the risk of PC-AKI before intravascular CM is
administered is best done by measuring eGFR but the alterna-
tive of a questionnaire for patients detects most patients with
eGFR less than 45 ml/min/1.73 m2. Volume expansion with
normal saline or sodium bicarbonate remains the mainstay of
PC-AKI prevention, but there is still uncertainty about the
optimal protocol. The additional benefit of a number of drugs,
such as N-acetylcysteine, statins, ACE inhibitors and
angiotensin-II receptor blockers, and vitamin C in preventing
PC-AKI has not been proved conclusively. Stopping nephro-
toxic medications appears to be of limited value in preventing
PC-AKI. Recommendations for discontinuing metformin
when CM is given have been relaxed and now only apply to
patients with eGFR < 30 ml/min/1.73 m2 receiving IV CM or
IA CM with second pass renal exposure, and to all patients
receiving IA CM with first pass renal exposure or who have
AKI. There is no need to adapt dialysis schedules in patients
being given intravascular CM.
The recommendations made in this paper have been incor-
porated into the ESURCMSC guidelines version 10 (Table 4).
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